{
  "docId": "019de076-0505-71be-a3a1-1067f47d4f96",
  "docSlug": "246b804be07776f664c6b3d8600daf3e",
  "documentTitle": "MAIA Biotechnology | Investor Presentation Deck | 39 slides",
  "authorId": "maia-biotechnology",
  "authorName": "MAIA Biotechnology",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 28,
  "pageCount": 39,
  "prevPage": 27,
  "nextPage": 29,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide presents two line charts showing tumor volume reduction over time for different treatment regimens in SCLC and HCC mouse models.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-0505-71be-a3a1-1067f47d4f96/28",
  "deckHref": "/decks/019de076-0505-71be-a3a1-1067f47d4f96",
  "deckJsonHref": "/decks/019de076-0505-71be-a3a1-1067f47d4f96.json",
  "deckAnchorHref": "/decks/019de076-0505-71be-a3a1-1067f47d4f96#slide-28",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.4,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "chart",
      "text": "SCLC tumor volume over time",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "02ca9ecc-9def-4502-b4ac-569fac6b59db",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.4,
        "x": 0.55,
        "y": 0.15
      },
      "kind": "chart",
      "text": "HCC tumor volume over time",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ea1f5ddb-1e1e-4f02-bc10-f1c3a210cd4a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.45,
        "x": 0.52,
        "y": 0.65
      },
      "kind": "list",
      "text": "THIO is highly synergistic and effective in combination with anti-PD-L1 agent Atezolizumab and Ionizing Radiation (IR 10Gy) in HCC53N Hepatocellular Carcinoma. Treatment with THIO in combination with IR and Atezolizumab results in complete regression.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4e2aa048-183d-4cfc-bfda-9f3cdd877e31",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.45,
        "x": 0.05,
        "y": 0.65
      },
      "kind": "list",
      "text": "THIO is synergistic with anti-PD-1 agent Pembrolizumab in Small Cell Lung Carcinoma (H2081) in vivo in humanized murine cancer model. Treatment with THIO followed by Pembrolizumab results in highly potent anticancer effect. THIO converts cold tumors to hot.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "99cea196-3cd5-4cd6-a136-22fe7e91e043",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.05,
        "y": 0.03
      },
      "kind": "title",
      "text": "SCLC & HCC – ORPHAN DRUG DESIGNATION",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "62b2565e-097b-4424-8f1c-c5eb53c469f4",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}